Blog
Tiragolumab Biosimilar: Enhancing Immune Checkpoint Therapy with TIGIT Inhibition
Tiragolumab is a monoclonal antibody targeting TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activity i
…
12th Dec 2024